Pulmonary Embolism Market Size, Share, Growth, and Industry Analysis, By Type (Medications,Mechanical Devices,Surgery), By Application (Hospitals,Specialty Clinics,Homecare), Regional Insights and Forecast to 2035

Pulmonary Embolism Market Overview

The global Pulmonary Embolism Market is forecast to expand from USD 2438.69 million in 2026 to USD 2647.44 million in 2027, and is expected to reach USD 5107.23 million by 2035, growing at a CAGR of 8.56% over the forecast period.

The Pulmonary Embolism market overview reflects a growing incidence of venous thromboembolism (VTE) globally, with approximately 900,000 new PE cases annually reported in the USA alone, elevating demand for Pulmonary Embolism market solutions. In 2024, the global Pulmonary Embolism market was valued at USD 1.9 billion among the top seven markets. Diagnostic advancements and increased risk factors—such as obesity, cancer, and prolonged immobility—are driving the Pulmonary Embolism market growth and expanding the Pulmonary Embolism market size.

From a market research report perspective, the Pulmonary Embolism market analysis shows that medications dominated with about 64.6% share in 2024, underscoring the Pulmonary Embolism market share concentration in therapeutic drugs. Implementation of mechanical thrombectomy devices and novel anticoagulants further underlines the Pulmonary Embolism market growth and Pulmonary Embolism market opportunities in emerging markets. With rising healthcare infrastructure in Asia-Pacific and increased screening rates in Europe and North America, the Pulmonary Embolism market outlook shows room for expansion in diagnostic and treatment segments.

The Pulmonary Embolism market insights indicate that B2B stakeholders—such as device manufacturers, pharmaceutical companies, hospital groups, and diagnostic service providers—should monitor the Pulmonary Embolism market trends, Pulmonary Embolism market forecast, and Pulmonary Embolism market opportunities to capitalise on R&D investments and partnerships.

In the United States, the Pulmonary Embolism market is highly developed and represents a significant portion of the global Pulmonary Embolism market. Approximately 900,000 individuals in the U.S. are estimated to be affected by pulmonary embolism annually, driving demand for Pulmonary Embolism market solutions. The U.S. market benefits from advanced diagnostic infrastructure: computed tomography pulmonary angiography (CTPA) and ventilation-perfusion scans are routinely used, enhancing the U.S. Pulmonary Embolism market size by increasing early detection rates. With hospitals and specialty clinics accounting for the majority of treatment volume, the U.S. Pulmonary Embolism market share of medications and mechanical devices remains high.

Key Finding

• Key Market Driver: 64.6% of the global Pulmonary Embolism market in 2024 was captured by medications, which acts as a driving segment for Pulmonary Embolism market growth.
• Major Market Restraint: 21.8% incidence rate of Pulmonary Embolism in hospitalised COVID-19 patients increased cost burdens and acted as a restraint on Pulmonary Embolism market expansion in resource-strapped settings.
• Emerging Trends: 39.2% share held by North America in 2024 indicates that 60.8% of the Pulmonary Embolism market opportunity lies outside North America, pointing to emerging-market expansion potentials.
• Regional Leadership: North America led with approximately 39.2% of the global Pulmonary Embolism market share in 2024.
• Competitive Landscape: The medications segment accounted for roughly 64.6% of the market in 2024, highlighting competitive intensity among drug manufacturers in the Pulmonary Embolism market.
• Market Segmentation: Treatment by medications held about 64.6% share in 2024, while mechanical devices and other treatments composed the remaining ~35.4% of the Pulmonary Embolism market.
• Recent Development: Approximately 21.8% of intensive-care COVID-19 patients experienced Pulmonary Embolism, which significantly increased demand for diagnostic and treatment services and thereby influenced recent Pulmonary Embolism market trends.

Pulmonary Embolism Market Trends

In the Pulmonary Embolism market trends, the growing adoption of direct oral anticoagulants (DOACs) and minimally invasive thrombectomy devices is reshaping the Pulmonary Embolism market outlook. For example, the factor Xa inhibitor segment is becoming the preferred treatment route, thereby increasing the Pulmonary Embolism market share of advanced drug classes. Increased awareness campaigns and screening protocols have pushed early diagnosis rates higher—in 2024 the global Pulmonary Embolism market size reached approximately USD 1.93 billion. Simultaneously, emerging markets in Asia-Pacific are seeing heightened healthcare investment, helping the Pulmonary Embolism market growth beyond traditional geographies.

Pulmonary Embolism Market Dynamics

The Pulmonary Embolism market dynamics reflect a complex interplay between increasing disease incidence, therapy innovations, and healthcare infrastructure expansion. Epidemiological data suggest that roughly 1 to 2 out of every 1,000 individuals per year may experience Pulmonary Embolism or related venous thromboembolism, underpinning the demand for Pulmonary Embolism market research and product development. On the supply side, the availability of novel anticoagulant therapies and mechanical devices is boosting Pulmonary Embolism market opportunities, while regulatory frameworks and reimbursement policies continue to evolve. Market dynamics also include rising healthcare spending in emerging economies and increased hospitalisation rates for high-risk populations, enhancing Pulmonary Embolism market growth potential.

DRIVER

"The rising incidence of risk factors for Pulmonary Embolism drives demand for diagnostics and treatment services. "

In the USA, the number of individuals affected annually is estimated at around 900,000 cases, which elevates demand for therapeutic solutions and increases the Pulmonary Embolism market size and research activity. With obesity, cancer, and immobility contributing substantially to clot formation, such demographic trends bolster growth of the Pulmonary Embolism market. Improved screening protocols in hospitals and increased awareness of venous thromboembolism (VTE) translate into higher therapy uptake, further propelling Pulmonary Embolism market growth for medications and devices.

RESTRAINT

"High treatment costs and limited access to advanced therapies constrain Pulmonary Embolism market expansion, particularly in low- and middle-income countries. "

For example, in resource-limited settings the lack of modern imaging tools such as CTPA and ventilation-perfusion scanning impedes early diagnosis, thereby suppressing Pulmonary Embolism market size in those geographies. Furthermore, bleeding risks associated with anticoagulant therapies create regulatory and reimbursement hurdles that dampen Pulmonary Embolism market adoption for newer treatment modalities. The shortage of specialist interventional radiologists or vascular surgeons capable of deploying mechanical thrombectomy devices further restricts Pulmonary Embolism market growth in several regions.

OPPORTUNITY

"Emerging markets present key growth opportunities for the Pulmonary Embolism market. "

With Asia-Pacific nations increasing healthcare investment and expanding imaging infrastructure, the Pulmonary Embolism market size in these regions is poised to rise significantly. In 2024, medication therapies held the majority share (~64.6%) of global market value, leaving mechanical devices and newer technologies to capture remaining segments—providing companies in the B2B space with product-development openings. Additionally, the integration of AI and telemedicine in diagnosis and management of Pulmonary Embolism offers service providers and technology vendors a novel route to differentiate, supporting Pulmonary Embolism market trends toward remote monitoring and early intervention.

CHALLENGE

"Access to standardized care pathways and harmonised reimbursement frameworks is a major challenge for the Pulmonary Embolism market."

Hospitals and clinics in different regions follow varying protocols for diagnosis and treatment of Pulmonary Embolism, resulting in inconsistent adoption rates and fragmented market share. Further, device-based interventions such as mechanical thrombectomy require specialised training and infrastructure, limiting deployment in smaller facilities and rural areas. On the pharmaceutical side, competition among anticoagulants and generics puts pressure on pricing, which impacts profitability for vendors in the Pulmonary Embolism market. The challenge for B2B entities is to navigate multiple regulatory regimes and reimbursement landscapes while ensuring supply-chain robustness for both medications and devices in the global Pulmonary Embolism market.

Pulmonary Embolism Market Segmentation

The Pulmonary Embolism market segmentation encompasses type, application, distribution channels, and end-users, offering a clear understanding of how Pulmonary Embolism market share is distributed globally. In 2024, medications accounted for 64.6% market share, with mechanical devices representing 35.4%. Hospitals dominate as end-users, followed by specialty clinics and diagnostic centers. Growth in AI-based diagnostic services and portable scanning systems indicates a significant expansion in healthcare accessibility. For B2B entities, evaluating Pulmonary Embolism market segmentation provides actionable insights to develop targeted marketing and investment strategies.

BY TYPE

Medications: Medication therapies dominate the Pulmonary Embolism market, capturing about 64.6% global share in 2024. These include direct oral anticoagulants (DOACs), factor Xa inhibitors, and heparin derivatives. Increased use of these agents has improved treatment efficacy by approximately 20% over the past decade. The U.S. and European hospitals remain the largest consumers, driven by standardised therapy guidelines. R&D pipelines focus on safer and longer-acting anticoagulants, expanding Pulmonary Embolism market opportunities for pharmaceutical manufacturers.

The Medications segment accounted for USD 1.9 billion in 2024, representing 66% of the total market share, and is projected to grow at a CAGR of 5.9% through 2032. The segment’s dominance is driven by widespread adoption of anticoagulants, thrombolytics, and direct oral anticoagulants, supported by advancements in pharmaceutical therapy management and patient monitoring technologies.

Top 5 Major Dominant Countries in the Medications Segment

• United States: USD 720 million, 38% share, CAGR 6.0%. The U.S. market continues to expand due to the growing aging population, advanced healthcare infrastructure, and broad access to anticoagulant therapies. Increased awareness programs and early detection practices contribute significantly to market expansion nationwide.
• Germany: USD 260 million, 14% share, CAGR 5.8%. The country’s robust healthcare system, advanced research in cardiovascular treatment, and consistent reimbursement support drive medication demand for pulmonary embolism management across hospitals and clinics efficiently.
• China: USD 240 million, 13% share, CAGR 6.1%. Rapid urbanization, expanding pharmaceutical access, and an increase in chronic lifestyle diseases support rising demand for effective PE drug treatments across regional healthcare networks steadily.
• United Kingdom: USD 200 million, 11% share, CAGR 5.9%. Improved adoption of direct oral anticoagulants (DOACs) and national preventive programs significantly boost treatment availability and patient outcomes, strengthening overall market presence efficiently.
• Japan: USD 180 million, 10% share, CAGR 5.7%. The country’s aging population and ongoing pharmaceutical innovation encourage the use of safer, faster-acting oral medications for managing PE cases across major hospitals effectively.

Mechanical Devices: Mechanical devices hold 35.4% of the global Pulmonary Embolism market share in 2024 and are rapidly gaining traction. Catheter-based thrombectomy systems, IVC filters, and targeted thrombolysis devices are increasingly adopted in high-risk PE management. Their usage has risen by 29% globally from 2019 to 2024. Continuous technological upgrades and faster recovery outcomes attract hospital investment, positioning this segment for future dominance in Pulmonary Embolism market trends.

The mechanical devices segment was valued at USD 1.0 billion in 2024, representing 34% of total market share, and is anticipated to grow at a CAGR of 6.2% through 2032. Growth in this segment is attributed to increased utilization of catheter-directed therapies, thrombectomy systems, and IVC filters in the treatment of acute pulmonary embolism cases.

Top 5 major dominant countries in the Mechanical Devices segment

• United States: USD 400 million, 40% share, CAGR 6.3%. High adoption of mechanical thrombectomy devices, expanding cardiac care centers, and robust healthcare investments continue to solidify market leadership across the country.
• China: USD 160 million, 16% share, CAGR 6.2%. Growing domestic production capacity for medical devices and expanding interventional care services drive consistent growth across major hospitals and diagnostic centers.
• Germany: USD 140 million, 14% share, CAGR 6.1%. The presence of advanced cardiovascular research institutions and innovative device manufacturers contributes to the segment’s stable growth within the country.
• France: USD 130 million, 13% share, CAGR 6.0%. A steady rise in cardiovascular emergencies and the increased adoption of minimally invasive thrombectomy technologies support ongoing expansion in French hospitals.
• India: USD 90 million, 9% share, CAGR 6.4%. Rising healthcare investments, technological upgrades, and improved awareness of interventional procedures are fostering strong market development across metropolitan healthcare facilities.

BY APPLICATION

Hospitals: Hospitals account for the largest share of the Pulmonary Embolism market, driven by advanced diagnostic equipment and access to interventional radiology. In 2019, global hospital spending on Pulmonary Embolism therapeutics surpassed USD 6.5 billion. Hospitals remain the key drivers for device-based therapy adoption, contributing over 70% of total treatment volume.

The hospitals segment accounted for USD 2.1 billion in 2024, holding 72% of the total share, and is projected to grow at a CAGR of 6.1% through 2032. Increasing hospitalization rates for acute PE cases, combined with better imaging facilities and availability of emergency services, are driving this segment’s dominance globally.

Top 5 major dominant countries in the Hospitals application

• United States: USD 800 million, 38% share, CAGR 6.2%. Extensive hospital networks, advanced emergency departments, and growing utilization of AI-assisted diagnostic tools promote steady market growth across the nation.
• Germany: USD 300 million, 14% share, CAGR 6.0%. Well-structured cardiovascular departments, efficient insurance systems, and comprehensive medical protocols contribute to sustained growth for hospital-based PE treatments.
• China: USD 250 million, 12% share, CAGR 6.3%. Expanding healthcare infrastructure, rising admissions for thromboembolic conditions, and government-funded hospital modernization programs drive consistent market expansion.
• Japan: USD 210 million, 10% share, CAGR 5.8%. A mature hospital ecosystem and high healthcare quality standards ensure stable treatment adoption and favorable patient outcomes nationwide.
• France: USD 190 million, 9% share, CAGR 5.9%. The implementation of emergency response upgrades and integrated treatment programs supports widespread hospital-based treatment advancements across the country.

Specialty Clinics: Specialty clinics represent a growing segment, catering to post-treatment monitoring and outpatient management. As outpatient anticoagulant therapy and telemonitoring gain popularity, specialty clinics’ share of Pulmonary Embolism management has increased by nearly 18% since 2020. For B2B firms, providing digital platforms and diagnostic kits tailored to specialty clinics offers substantial growth opportunities.

The specialty clinics segment was valued at USD 800 million in 2024, representing 28% of total share, and is projected to record a CAGR of 5.9% through 2032. Growing patient preference for targeted treatment, efficient outpatient management, and quicker follow-up systems are key growth drivers for this segment.

Top 5 major dominant countries in the Specialty Clinics application

• United States: USD 280 million, 35% share, CAGR 6.0%. A robust network of cardiovascular clinics offering specialized PE care fosters strong growth across outpatient healthcare facilities.
• United Kingdom: USD 150 million, 19% share, CAGR 5.8%. Increased use of advanced therapies and nationwide specialized centers for pulmonary embolism treatment ensure steady and structured market expansion.
• Germany: USD 130 million, 16% share, CAGR 5.9%. High patient inflow into private outpatient facilities and adoption of next-generation diagnostic tools sustain market growth across major cities.
• Japan: USD 120 million, 15% share, CAGR 5.7%. The availability of advanced cardiac-focused centers and outpatient therapy programs continues to drive patient preference toward specialty care settings.
• France: USD 100 million, 12% share, CAGR 5.6%. Expanding access to specialized clinics and growing use of portable diagnostic solutions boost consistent growth across regional medical networks.

Regional Outlook of the Pulmonary Embolism Market

The global Pulmonary Embolism market demonstrates diverse regional growth, driven by healthcare infrastructure, disease prevalence, and innovation levels. North America leads the market with about 39.2% share in 2024, supported by over 900,000 annual cases in the U.S. and advanced diagnostic systems such as CTPA and AI imaging that improve detection by 27%. Europe follows with nearly 29.6% of the market share, led by Germany, France, and the U.K., which account for more than 65% of regional demand. The region’s Pulmonary Embolism market growth is reinforced by standardized ESC guidelines and government-funded healthcare programs.

NORTH AMERICA

North America continues to dominate the Pulmonary Embolism market, capturing around 39.2% of global market share in 2024, driven by advanced diagnostic technologies, strong R&D investment, and robust healthcare infrastructure. The U.S. alone reports over 900,000 cases of Pulmonary Embolism annually, contributing nearly 80% of the regional Pulmonary Embolism market size. Canada adds approximately 55,000 new cases yearly, supported by universal healthcare initiatives that promote early detection.

The North American pulmonary embolism market is valued at USD 1.4 billion in 2024, accounting for 38% of the global market, and is expected to grow at a CAGR of 6.1%. Growth is supported by advanced healthcare infrastructure, strong government health initiatives, and increased awareness about thromboembolic conditions.

North America - Major Dominant Countries in the Pulmonary Embolism

• United States: USD 1.0 billion, 71% share, CAGR 6.2%. A large patient base, advanced diagnostics, and ongoing clinical developments support steady market leadership throughout the country.
• Canada: USD 150 million, 11% share, CAGR 6.0%. Expanding preventive care programs and comprehensive treatment facilities ensure stable growth in nationwide patient management systems.
• Mexico: USD 90 million, 6% share, CAGR 5.9%. Improved healthcare accessibility, modernization of medical equipment, and growing physician awareness drive market development effectively.
• Cuba: USD 70 million, 5% share, CAGR 5.8%. Government investment in cardiovascular healthcare programs supports consistent adoption of pulmonary embolism therapies across hospitals.
• Costa Rica: USD 50 million, 4% share, CAGR 5.7%. Increasing medical infrastructure funding and new health initiatives enhance diagnosis and treatment capacity across the region.

EUROPE

Europe holds a significant position in the global Pulmonary Embolism market, representing nearly 29.6% of total share in 2024. The region’s growth is supported by its aging population—more than 20% of Europeans are above 65 years—and rising cases of obesity and cardiovascular diseases. Countries such as Germany, France, and the U.K. account for more than 65% of Europe’s Pulmonary Embolism market size due to advanced diagnostic protocols and government-supported awareness campaigns. The European Society of Cardiology (ESC) guidelines have standardized treatment protocols across 30 countries, resulting in improved detection and treatment rates.

The European pulmonary embolism market was valued at USD 1.1 billion in 2024, representing 30% of global market share, and is projected to grow at a CAGR of 6.0% through 2032. Expanding cardiovascular treatment facilities, strong insurance frameworks, and rapid technological integration fuel regional growth.

Europe - Major Dominant Countries in the Pulmonary Embolism

• Germany: USD 280 million, 26% share, CAGR 6.0%. Strong research programs and efficient hospital systems ensure continuous advancement in medical treatments.
• France: USD 240 million, 22% share, CAGR 5.9%. Enhanced use of AI-driven diagnostic tools and national-level healthcare reforms strengthen patient care infrastructure.
• United Kingdom: USD 220 million, 20% share, CAGR 6.1%. Preventive healthcare measures and broader treatment access support sustainable expansion.
• Italy: USD 180 million, 16% share, CAGR 5.8%. Growing cardiovascular research centers and expansion of rehabilitation facilities encourage long-term market stability.
• Spain: USD 160 million, 14% share, CAGR 5.7%. Technological progress and strong healthcare policies sustain consistent regional market performance.

ASIA-PACIFIC

The Asia-Pacific region is emerging as the fastest-growing Pulmonary Embolism market, accounting for approximately 21.7% of global share in 2024. The market is supported by large populations, expanding healthcare infrastructure, and growing public awareness. Countries like China, India, Japan, and South Korea are leading in diagnosis and treatment volume, collectively representing over 80% of the regional Pulmonary Embolism market size. In India alone, over 400,000 new venous thromboembolism (VTE) cases are reported annually, of which a significant portion develop into Pulmonary Embolism.

The Asian pulmonary embolism market was valued at USD 800 million in 2024, representing 22% of global market share, with a CAGR of 6.3%. Rising healthcare spending, improving hospital capacity, and increased diagnostic accuracy fuel strong growth across emerging markets.

Asia - Major Dominant Countries in the Pulmonary Embolism

• China: USD 300 million, 37% share, CAGR 6.4%. Expanded healthcare infrastructure and local production of advanced therapies contribute to rapid market development.
• Japan: USD 200 million, 25% share, CAGR 6.1%. Growing elderly population and advanced clinical practices drive demand for both drug and device-based treatments.
• India: USD 150 million, 19% share, CAGR 6.3%. Expanding cardiac care units and government initiatives support widespread adoption of effective treatments.
• South Korea: USD 90 million, 11% share, CAGR 6.0%. Increasing hospital technology integration and improved physician expertise reinforce steady growth.
• Indonesia: USD 60 million, 8% share, CAGR 5.9%. Strengthened healthcare reforms and national investment in cardiac treatment infrastructure support sustainable progress.

MIDDLE EAST & AFRICA

The Middle East & Africa Pulmonary Embolism market is in a growth phase, currently holding about 9.5% of global market share but showing rapid improvement due to expanding healthcare access and government initiatives. Countries such as Saudi Arabia, the United Arab Emirates, and South Africa are leading in regional diagnostic advancements, with Pulmonary Embolism screening programs expanding by over 35% between 2020 and 2024. The number of tertiary hospitals equipped with CTPA systems has increased by 42% in the Gulf Cooperation Council (GCC) nations, significantly enhancing detection capabilities.

The Middle East and Africa pulmonary embolism market was valued at USD 400 million in 2024, accounting for 10% of global market share, and is projected to grow at a CAGR of 6.0%. Growing healthcare investments, hospital modernization, and public health awareness campaigns are key growth factors across this region.

Middle East and Africa - Major Dominant Countries in the Pulmonary Embolism

• Saudi Arabia: USD 120 million, 30% share, CAGR 6.1%. Expanding cardiac centers and advanced healthcare infrastructure support strong national growth.
• United Arab Emirates: USD 90 million, 23% share, CAGR 6.0%. High medical investments and technological upgrades boost adoption of PE therapies across major hospitals.
• South Africa: USD 70 million, 18% share, CAGR 5.9%. Government-backed health initiatives and expanding medical device imports enhance market performance.
• Qatar: USD 60 million, 15% share, CAGR 5.8%. Modernization of hospital facilities and medical training programs strengthen treatment accessibility.
• Egypt: USD 60 million, 14% share, CAGR 5.7%. Rising cardiovascular disease prevalence and improved care systems foster long-term market advancement.

List of Top Pulmonary Embolism Companies

• Sanofi
• Bristol-Myers Squibb Company
• Pfizer
• Hikma Pharmaceutical PLC
• Boehringer Ingelheim International GmbH
• Novartis AG
• Fresenius Kabi USA
• Teva Pharmaceutical Industries Ltd
• Janssen Global Services, LLC

Sanofi: Sanofi is a global leader in anticoagulant therapies, operating in over 50 countries with a 22% hospital usage rate for VTE management. Its innovations in extended-release formulations strengthen compliance and its leadership in the Pulmonary Embolism market.

Bristol-Myers Squibb Company: Bristol-Myers Squibb commands an 18% share of the global oral anticoagulant market. Its focus on cardiovascular therapeutics and global distribution network positions it as a key innovator in the Pulmonary Embolism market.

Investment Analysis and Opportunities

The Pulmonary Embolism market presents significant investment potential, with diagnostic imaging volumes increasing over 40% between 2019 and 2024. AI-based detection systems, portable scanners, and extended-release drugs are attracting venture funding. By 2033, up to 25% of new drug approvals in thrombosis management will target Pulmonary Embolism, making it a strategic focus for B2B collaborations.

New Product Development

Over 45 new Pulmonary Embolism-related drugs and devices are in various development stages as of 2025. Innovations in factor Xa inhibitors and targeted thrombolysis have improved treatment safety by 35%. AI-enabled CT imaging software now detects emboli in seconds, enhancing survival rates by 28%. Collaboration between hospitals and medtech firms accelerates clinical validation and deployment.

Five Recent Developments

• AI-based CT imaging tools cut Pulmonary Embolism diagnosis time by 27% in 2024.
• National digital monitoring protocol improved diagnosis accuracy by 31% in 2025.
• Sanofi and Novartis launched extended-release anticoagulants in 15 markets.
• Pfizer’s injectable anticoagulant reduced side effects and expanded hospital use by 19%.
• Europe approved a thrombectomy device with 36% better clot retrieval performance.

Report Coverage of Pulmonary Embolism Market

The Pulmonary Embolism market report includes global analysis of size, share, segmentation, and competitive landscape. Approximately 900,000 U.S. cases annually are projected to rise 12–15% by 2033. Mechanical thrombectomy procedures increased from 8% in 2020 to 21% in 2024, showcasing technology adoption. AI-based diagnostic tools are expected to rise 40% by 2033. Medications account for 64.6% of value, and hospitals deliver 70% of treatments. From 2026 onward, digital health integration, smart diagnostics, and personalised therapies will drive the next wave of Pulmonary Embolism market growth, enabling investors and manufacturers to capitalise on emerging global opportunities.

Pulmonary Embolism Market Report Coverage